| Multiple Sclerosis |
1 |
1 |
| Biologic Therapy |
0 |
0.99 |
| Biosimilars |
0 |
0.98 |
| Monoclonal Antibody |
0 |
0.21 |
| Humanized Monoclonal Antibody |
0 |
0.18 |
| Adverse Effects |
0 |
0.1 |
| Disability |
0 |
0.1 |
| Patient Safety |
0 |
0.09 |
| Progressive Multifocal Leukoencephalopathy |
0 |
0.07 |
| Board Certification |
0 |
0.05 |
| Brain |
0 |
0.05 |
| Central Nervous System |
0 |
0.05 |
| Demyelination |
0 |
0.05 |
| Disease-Modifying Therapy |
0 |
0.05 |
| Europe |
0 |
0.05 |
| Florida |
0 |
0.05 |
| Genetics |
0 |
0.05 |
| Grant |
0 |
0.05 |
| Infestations |
0 |
0.05 |
| Interferon Beta |
0 |
0.05 |
| Intravenous |
0 |
0.05 |
| JC Virus |
0 |
0.05 |
| Leukoencephalopathy |
0 |
0.05 |
| Match |
0 |
0.05 |
| Multiple Sclerosis Treatment |
0 |
0.05 |
| Polyomavirus |
0 |
0.05 |
| Relapsing Remitting Multiple Sclerosis |
0 |
0.05 |
| Genomic Medicine |
0 |
0.04 |